Source guides · 24
- PubMed 36332827 · O'Donnell KC, Mennenga SE, Owens LT, Podrebarac SK, Baron T, Rotrosen J, Ross S, Forcehimes AA, Bogenschutz MP. Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trial. Contemp Clin Trials. 2022 Dec;123:106976. doi: 10.1016/j.cct.2022.106976. Epub 2022 Nov 2. · Full Atlas view
- PubMed 36369028 · Halff EF, Rutigliano G, Garcia-Hidalgo A, Howes OD. Trace amine-associated receptor 1 (TAAR1) agonism as a new treatment strategy for schizophrenia and related disorders. Trends Neurosci. 2023 Jan;46(1):60-74. doi: 10.1016/j.tins.2022.10.010. Epub 2022 Nov 8. · Full Atlas view
- PubMed 36414626 · Sauder C, Allen LA, Baker E, Miller AC, Paul SM, Brannan SK. Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study. Transl Psychiatry. 2022 Nov 21;12(1):491. doi: 10.1038/s41398-022-02254-9. · Full Atlas view
- PubMed 37086340 · Good M, Joel Z, Benway T, Routledge C, Timmermann C, Erritzoe D, Weaver R, Allen G, Hughes C, Topping H, Bowman A, James E. Pharmacokinetics of N,N-dimethyltryptamine in Humans. Eur J Drug Metab Pharmacokinet. 2023 May;48(3):311-327. doi: 10.1007/s13318-023-00822-y. Epub 2023 Apr 22. · Full Atlas view
- PubMed 37276086 · Agin-Liebes G, Nielson EM, Zingman M, Kim K, Haas A, Owens LT, Rogers U, Bogenschutz M. Reports of self-compassion and affect regulation in psilocybin-assisted therapy for alcohol use disorder: An interpretive phenomenological analysis. Psychol Addict Behav. 2024 Feb;38(1):101-113. doi: 10.1037/adb0000935. Epub 2023 Jun 5. · Full Atlas view
- PubMed 37361338 · McCaffrey J, Hunter A. Protocol Development for a Qualitative Methodological Study Within a Trial (Qual-SWAT): The KARMA-Dep-2 Trial. HRB Open Res. 2023 Nov 20;6:29. doi: 10.12688/hrbopenres.13721.2. eCollection 2023. · Full Atlas view
- PubMed 37439961 · Jamieson C, Canuso CM, Ionescu DF, Lane R, Qiu X, Rozjabek H, Molero P, Fu DJ. Effects of esketamine on patient-reported outcomes in major depressive disorder with active suicidal ideation and intent: a pooled analysis of two randomized phase 3 trials (ASPIRE I and ASPIRE II). Qual Life Res. 2023 Nov;32(11):3053-3061. doi: 10.1007/s11136-023-03451-9. Epub 2023 Jul 13. · Full Atlas view
- PubMed 37520237 · Lear MK, Smith SM, Pilecki B, Stauffer CS, Luoma JB. Social anxiety and MDMA-assisted therapy investigation: a novel clinical trial protocol. Front Psychiatry. 2023 Jul 14;14:1083354. doi: 10.3389/fpsyt.2023.1083354. eCollection 2023. · Full Atlas view
- PubMed 37568081 · Fu DJ, Zhang Q, Shi L, Borentain S, Guo S, Mathews M, Anjo J, Nash AI, O'Hara M, Canuso CM. Esketamine versus placebo on time to remission in major depressive disorder with acute suicidality. BMC Psychiatry. 2023 Aug 11;23(1):587. doi: 10.1186/s12888-023-05017-y. · Full Atlas view
- PubMed 37709999 · Mitchell JM, Ot'alora G M, van der Kolk B, Shannon S, Bogenschutz M, Gelfand Y, Paleos C, Nicholas CR, Quevedo S, Balliett B, Hamilton S, Mithoefer M, Kleiman S, Parker-Guilbert K, Tzarfaty K, Harrison C, de Boer A, Doblin R, Yazar-Klosinski B; MAPP2 Study Collaborator Group. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat Med. 2023 Oct;29(10):2473-2480. doi: 10.1038/s41591-023-02565-4. Epub 2023 Sep 14. · Full Atlas view
- PubMed 37974160 · Jelovac A, McCaffrey C, Terao M, Shanahan E, Mohamed E, Whooley E, McDonagh K, McDonogh S, Igoe A, Loughran O, Shackleton E, O'Neill C, McLoughlin DM. Study protocol for Ketamine as an adjunctive therapy for major depression (2): a randomised controlled trial (KARMA-Dep [2]). BMC Psychiatry. 2023 Nov 16;23(1):850. doi: 10.1186/s12888-023-05365-9. · Full Atlas view
- PubMed 38104575 · Kaul I, Sawchak S, Correll CU, Kakar R, Breier A, Zhu H, Miller AC, Paul SM, Brannan SK. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial. Lancet. 2024 Jan 13;403(10422):160-170. doi: 10.1016/S0140-6736(23)02190-6. Epub 2023 Dec 14. · Full Atlas view
- PubMed 38198456 · van der Kolk BA, Wang JB, Yehuda R, Bedrosian L, Coker AR, Harrison C, Mithoefer M, Yazar-Klosinki B, Emerson A, Doblin R. Effects of MDMA-assisted therapy for PTSD on self-experience. PLoS One. 2024 Jan 10;19(1):e0295926. doi: 10.1371/journal.pone.0295926. eCollection 2024. · Full Atlas view
- PubMed 38274414 · James E, Erritzoe D, Benway T, Joel Z, Timmermann C, Good M, Agnorelli C, Weiss BM, Barba T, Campbell G, Baker Jones M, Hughes C, Topping H, Boyce M, Routledge C. Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participants: a randomized, placebo-controlled phase 1 trial. Front Psychiatry. 2024 Jan 11;14:1305796. doi: 10.3389/fpsyt.2023.1305796. eCollection 2023. · Full Atlas view
- PubMed 38326432 · Pagni BA, Petridis PD, Podrebarac SK, Grinband J, Claus ED, Bogenschutz MP. Psilocybin-induced changes in neural reactivity to alcohol and emotional cues in patients with alcohol use disorder: an fMRI pilot study. Sci Rep. 2024 Feb 7;14(1):3159. doi: 10.1038/s41598-024-52967-8. · Full Atlas view
- PubMed 38691387 · Kaul I, Sawchak S, Walling DP, Tamminga CA, Breier A, Zhu H, Miller AC, Paul SM, Brannan SK. Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: A Randomized Clinical Trial. JAMA Psychiatry. 2024 Aug 1;81(8):749-756. doi: 10.1001/jamapsychiatry.2024.0785. · Full Atlas view
- PubMed 38988455 · Peck SK, Shao S, Gruen T, Yang K, Babakanian A, Trim J, Finn DM, Kaye WH. Psilocybin Therapy for Females With Anorexia Nervosa: A Phase 1, Open-Label Feasibility Study. Focus (Am Psychiatr Publ). 2024 Jul;22(3):381-387. doi: 10.1176/appi.focus.24022013. Epub 2024 Jun 28. · Full Atlas view
- PubMed 39262902 · Eaton E, Capone C, Gully BJ, Brown ZE, Monnig M, Worden MS, Swift RM, Haass-Koffler CL. Design and methodology of the first open-label trial of MDMA-assisted therapy for veterans with post-traumatic stress disorder and alcohol use disorder: Considerations for a randomized controlled trial. Contemp Clin Trials Commun. 2024 Jul 20;41:101333. doi: 10.1016/j.conctc.2024.101333. eCollection 2024 Oct. · Full Atlas view
- PubMed 39428602 · Vekhova KA, Namiot ED, Jonsson J, Schioth HB. Ketamine and Esketamine in Clinical Trials: FDA-Approved and Emerging Indications, Trial Trends With Putative Mechanistic Explanations. Clin Pharmacol Ther. 2025 Feb;117(2):374-386. doi: 10.1002/cpt.3478. Epub 2024 Oct 20. · Full Atlas view
- PubMed 39741446 · Pagni BA, Zeifman RJ, Mennenga SE, Carrithers BM, Goldway N, Bhatt S, O'Donnell KC, Ross S, Bogenschutz MP. Multidimensional Personality Changes Following Psilocybin-Assisted Therapy in Patients With Alcohol Use Disorder: Results From a Double-Blind, Placebo-Controlled Clinical Trial. Am J Psychiatry. 2025 Jan 1;182(1):114-125. doi: 10.1176/appi.ajp.20230887. · Full Atlas view
- PubMed 39839135 · Sabucedo P, Andion O, Neimeyer RA, Soto-Angona O, Javkin J, Haro JM, Farre M, Gonzalez D. Ayahuasca-assisted meaning reconstruction therapy for grief: a non-randomized clinical trial protocol. Front Psychiatry. 2025 Jan 7;15:1484736. doi: 10.3389/fpsyt.2024.1484736. eCollection 2024. · Full Atlas view
- PubMed 40047530 · Kaul I, Claxton A, Sawchak S, Sauder C, Brannan SK, Raj E, Ruan S, Konis G, Brown D, Cutler AJ, Marcus R. Safety and Tolerability of Xanomeline and Trospium Chloride in Schizophrenia: Pooled Results From the 5-Week, Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials. J Clin Psychiatry. 2025 Feb 26;86(1):24m15497. doi: 10.4088/JCP.24m15497. · Full Atlas view
- PubMed 40145363 · Ramey OL, Silva Almodovar A. Xanomeline-Trospium: A Novel Therapeutic for the Treatment of Schizophrenia. Ann Pharmacother. 2025 Oct;59(10):937-950. doi: 10.1177/10600280251324642. Epub 2025 Mar 27. · Full Atlas view
- PubMed 40212458 · Citrome L, Neugebauer NM, Meli AA, Kando J. Xanomeline and Trospium Chloride Versus Placebo for the Treatment of Schizophrenia: A Post Hoc Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed. Neuropsychiatr Dis Treat. 2025 Apr 5;21:761-773. doi: 10.2147/NDT.S503494. eCollection 2025. · Full Atlas view
- PubMed 40215379 · Yeung PP, Breier A, Zhu H, Kaul I, Marcus RN. Xanomeline and Trospium Chloride for the Treatment of Agitation Associated With Schizophrenia: PANSS-Excited Component Results From 3 Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials. J Clin Psychiatry. 2025 Mar 24;86(2):24m15668. doi: 10.4088/JCP.24m15668. · Full Atlas view
- PubMed 40337754 · Falchi-Carvalho M, Barros H, Bolcont R, Laborde S, Wiessner I, Ruschi B Silva S, Montanini D, Barbosa DC, Teixeira E, Florence-Vilela R, Almeida R, de Macedo RKA, Arichelle F, Pantrigo EJ, Costa-Macedo JV, Arcoverde E, Galvao-Coelho N, Araujo DB, Palhano-Fontes F. The Antidepressant Effects of Vaporized N,N-Dimethyltryptamine: An Open-Label Pilot Trial in Treatment-Resistant Depression. Psychedelic Med (New Rochelle). 2025 Feb 27;3(1):48-52. doi: 10.1089/psymed.2024.0002. eCollection 2025 Mar. · Full Atlas view
- PubMed 40375477 · Hagel JM, Chang L, Li J, Chen X, Yu L, Gallant JA, Facchini PJ. Bioproduction of a Large-Scale Library of Tryptamine Derivatives for Neuropsychiatric Drug Screening. ACS Chem Biol. 2025 Jun 20;20(6):1212-1231. doi: 10.1021/acschembio.4c00857. Epub 2025 May 15. · Full Atlas view
- PubMed 40484114 · Swieczkowski D, Kwasny A, Cubala WJ. Safety and tolerability of NN-dimethyltryptamine (DMT) in healthy volunteers and Major Depressive Disorder (MDD) patients: A systematic review of early-phase clinical trials. Prog Neuropsychopharmacol Biol Psychiatry. 2025 Jul 13;140:111419. doi: 10.1016/j.pnpbp.2025.111419. Epub 2025 Jun 7. · Full Atlas view
- PubMed 40492610 · Thurgur H, Sessa B, Higbed L, O'Brien S, Durant C, Wilson S, Szigeti B, Morgan CJA, Nutt DJ. MDMA-assisted psychotherapy for AUD: Bayesian analysis of WHO drinking risk level and exploratory analysis of drinking behavior and psychosocial functioning at 3 months follow-up. Alcohol Alcohol. 2025 May 14;60(4):agaf031. doi: 10.1093/alcalc/agaf031. · Full Atlas view
- PubMed 40883964 · McGowan NM, Rucker JJ, Yehuda R, Agrawal M, Modlin NL, Simmons H, Tofil-Kaluza A, Das S, Goodwin GM. Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial. J Psychopharmacol. 2026 Jan;40(1):139-148. doi: 10.1177/02698811251362390. Epub 2025 Aug 29. · Full Atlas view
- PubMed 40900112 · Kumpf KT, Wilkinson ST, Hu B, Chen R, Krishnan K, Chakrabarti S, Rhee TG, Grezmak T, Mathew SJ, Sanacora G, Murrough JW, Goes FS, Collins KA, Barnett BS, Anand A. Comparing the Cognitive Effects of Repeated Intravenous Ketamine and Electroconvulsive Therapy in Patients With Treatment-Resistant Depression: A Secondary Analysis of the ELEKT-D Trial. J Clin Psychiatry. 2025 Sep 3;86(4):25m15781. doi: 10.4088/JCP.25m15781. · Full Atlas view
- PubMed 41123905 · Jelovac A, McCaffrey C, Terao M, Shanahan E, Whooley E, McDonagh K, McDonogh S, Loughran O, Shackleton E, Igoe A, Thompson S, Mohamed E, Nguyen D, O'Neill C, Walsh C, McLoughlin DM. Serial Ketamine Infusions as Adjunctive Therapy to Inpatient Care for Depression: The KARMA-Dep 2 Randomized Clinical Trial. JAMA Psychiatry. 2025 Dec 1;82(12):1216-1224. doi: 10.1001/jamapsychiatry.2025.3019. · Full Atlas view
- PubMed 41497513 · Modlin NL, Williamson V, Goodwin GM, Malievskaia E, Atli M, Elek Z, Gaillard A, Koelpin D, Cleare A, Agrawal M, Yehuda R, Kirlic N, Rucker J. Investigational psilocybin treatment for post-traumatic stress disorder: a qualitative study of participant experience, trauma engagement, and differences from standard treatment. EClinicalMedicine. 2025 Dec 5;90:103692. doi: 10.1016/j.eclinm.2025.103692. eCollection 2025 Dec. · Full Atlas view
- PubMed 41730563 · Jacobs E, Zahid Z, Hinkle J, Nayak S, Yaden DB. Psychedelic medicine: mechanisms, evidence, and translation to practice. BMJ. 2026 Feb 23;392:e081723. doi: 10.1136/bmj-2024-081723. · Full Atlas view
- PubMed 41805956 · Johnson MW, Naude GP, Hendricks PS, Garcia-Romeu A. Psilocybin or Nicotine Patch for Smoking Cessation: A Pilot Randomized Clinical Trial. JAMA Netw Open. 2026 Mar 2;9(3):e260972. doi: 10.1001/jamanetworkopen.2026.0972. · Full Atlas view
- PubMed 41879760 · Cubala WJ, Bajbouj M, Bauer M, Baune BT, Cardoner N, Devlin F, Doolin K, Duenas Herrero RM, Elices M, Feeney A, Galuszko-Wegielnik M, Jakuszkowiak-Wojten K, Janu L, Kelly JR, Ledden K, Maclsaac R, Madero S, McInerney SJ, Montejo AL, Nawka A, Palenicek T, Perez Sola V, Ramaekers JG, Reif A, Ritter P, Ryan F, Svendsen CB, Sweeney C, Terwey TH, Trivedi MH, Valcheva V, Vieta E, Thase ME. GH001 vs Placebo in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2026 Jun 1;83(6):561-569. doi: 10.1001/jamapsychiatry.2026.0096. · Full Atlas view
- PubMed 42460632 · Dougherty RF, Modlin NL, McGowan NM, Staples P, Williams E, Clarke P, Shafiei M, Leininger C, Alti M, Croal M, Marwood L, Kirlic N, Ryslik GA, Goodwin GM. Silence is golden: Documenting the speech production of participants and support providers in psilocybin administration sessions for the treatment of post-traumatic stress disorder. J Psychopharmacol. 2026 Jul 16:2698811261464988. doi: 10.1177/02698811261464988. Online ahead of print. · Full Atlas view
- PubMed 42913354 · Pagni BA, Ross S, Mennenga S, Bhatt S, Zeifman RJ, Petridis PD, Carrithers BM, Worth L, Podrebarac S, Owens LT, O'Donnell K, Roberts DE, Kim Y, Bogenschutz MP. Safety and efficacy of psilocybin-assisted therapy for alcohol use disorder: Open-label extension of a phase II randomized controlled trial. Drug Alcohol Depend. 2026 Oct 15;288:113387. doi: 10.1016/j.drugalcdep.2026.113387. Online ahead of print. · Full Atlas view
- PubMed 43010266 · Wunderlich G, Blahova Z, Hake S, Ikezawa S, Marder S, Falkai P, Krystal JH. Efficacy and Safety of Iclepertin (BI 425809) in Patients With Schizophrenia: CONNEX, A Phase III Randomized Controlled Trial Program. CNS Spectr. 2023 Apr;28(2):229. doi: 10.1017/S1092852923001530. Epub 2023 Apr 14. · Full Atlas view
- PubMed 43010306 · Brannan SK, Cutler AJ, Sawchak S, Kando J, Miller AC, Claxton A, Paul SM, Kaul I. Safety and Tolerability of KarXT (Xanomeline Trospium): Pooled Results From the Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials. CNS Spectr. 2024 Oct;29(5):515. doi: 10.1017/S1092852924001901. Epub 2025 Jan 10. · Full Atlas view
- PubMed 43010364 · Kaul I, Citrome L, Sawchak S, Kando J, Miller AC, Paul SM, Brannan SK. Efficacy of KarXT (Xanomeline Trospium) in Schizophrenia: Pooled Results From the Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials. CNS Spectr. 2024 Oct;29(5):489-490. doi: 10.1017/S1092852924001445. Epub 2025 Jan 10. · Full Atlas view
- PubMed search for catatonia · Full Atlas view
- PubMed search · Additional investigational agents · Full Atlas view
- PubMed search · DMT and related preparations · Full Atlas view
- PubMed search · Ketamine / esketamine · Full Atlas view
- PubMed search · MDMA · Full Atlas view
- Published CONNEX phase 3 program · Full Atlas view
- Published PTSD open-label study · Full Atlas view
- Published correction to the veterans case series · Full Atlas view
- Published opening transcript excerpt · Full Atlas view
- Published phase 2b generalized anxiety trial · Full Atlas view
- Pulmonary embolism confounded with COVID-19 suspicion in a catatonic patient presenting to anesthesia for ECT: a case report. · Full Atlas view
- Pulmonary embolism confounded with COVID-19 suspicion in a catatonic patient presenting to anesthesia for ECT: a case report. · Full Atlas view
- Pulmonary embolism confounded with COVID-19 suspicion in a catatonic patient presenting to anesthesia for ECT: a case report. · Full Atlas view
- RECURRENT CATATONIA DUE TO EPISODIC OBSESSIVE-COMPULSIVE DISORDER: A CASE REPORT · Full Atlas view
- RECURRENT CATATONIA DUE TO EPISODIC OBSESSIVE-COMPULSIVE DISORDER: A CASE REPORT · Full Atlas view
- RIVER At Home Ketamine Protocols · Full Atlas view
- Randomized Controlled Trial of Intranasal Ketamine vs. Intranasal Midazolam in Individuals With OCD · Full Atlas view
- Randomized N,N-DMT study in major depression · Full Atlas view
- Randomized Placebo-controlled Study of MDMA-assisted Therapy in People With PTSD - Israel · Full Atlas view
- Randomized early schizophrenia trial · Full Atlas view
- Randomized ketamine psychotherapy study · Full Atlas view
- Randomized pilot in autistic adults · Full Atlas view
- Randomized wait-list trial in social anxiety disorder · Full Atlas view
- Randomized, Double-blind, Controlled of MDMA-assisted Psychotherapy in 12 Subjects With PTSD · Full Atlas view
- Randomized, Double-blind, Placebo-Controlled Pilot Study of MDMA-assisted Therapy for PTSD · Full Atlas view
- Rapid Antidepressant Effects of Ketamine in Major Depression · Full Atlas view
- Rapid Development of Lorazepam Tolerance Within 48 Hours in an Adult With Intellectual Disability Who Presented With Stuporous Catatonia and Refused Electroconvulsive Therapy. · Full Atlas view
- Rapid Development of Lorazepam Tolerance Within 48 Hours in an Adult With Intellectual Disability Who Presented With Stuporous Catatonia and Refused Electroconvulsive Therapy. · Full Atlas view
- Rapid ECT response in acute polymorphic psychosis · Full Atlas view
- Rapid Improvement of Persistent Catatonia Temporally Associated With Amantadine After Benzodiazepine Intolerance and Discontinuation of Electroconvulsive Therapy: A Case Report. · Full Atlas view
- Rapid Improvement of Persistent Catatonia Temporally Associated With Amantadine After Benzodiazepine Intolerance and Discontinuation of Electroconvulsive Therapy: A Case Report. · Full Atlas view
- Rapid Improvement of Persistent Catatonia Temporally Associated With Amantadine After Benzodiazepine Intolerance and Discontinuation of Electroconvulsive Therapy: A Case Report. · Full Atlas view
- Rapid Resolution of Prolonged Benzodiazepine-Refractory Catatonia With Electroconvulsive Therapy in an Adolescent Patient: A Case Report. · Full Atlas view
- Rapid Resolution of Prolonged Benzodiazepine-Refractory Catatonia With Electroconvulsive Therapy in an Adolescent Patient: A Case Report. · Full Atlas view
- Rapid Resolution of Prolonged Benzodiazepine-Refractory Catatonia With Electroconvulsive Therapy in an Adolescent Patient: A Case Report. · Full Atlas view
- Rapid Response of Long-Standing, Treatment-Resistant Non-Catatonic Mutism in Paranoid Schizophrenia with Single ECT session. · Full Atlas view
- Rapid Response of Long-Standing, Treatment-Resistant Non-Catatonic Mutism in Paranoid Schizophrenia with Single ECT session. · Full Atlas view
- Rapid Response of Long-Standing, Treatment-Resistant Non-Catatonic Mutism in Paranoid Schizophrenia with Single ECT session. · Full Atlas view
- Rapid efficacy of aripiprazole in the treatment of catatonic depression/catatonia with consideration of the drug's unique receptor profile: a case report. · Full Atlas view
- Rapid efficacy of aripiprazole in the treatment of catatonic depression/catatonia with consideration of the drug's unique receptor profile: a case report. · Full Atlas view
- Rapid symptom control in neuroleptic malignant syndrome with electroconvulsive therapy: A case report. · Full Atlas view
- Rapidly progressive global cerebral atrophy in the setting of anti-LGI1 encephalitis. · Full Atlas view
- Rare diseases with psychiatric manifestations, including catatonic syndrome · Full Atlas view
- Read the full transcript at NAMI · Full Atlas view
- Recognizing malignant illness · Full Atlas view
- Recognizing medical emergencies · Full Atlas view
- Recognizing sustained facial expressions · Full Atlas view
- Recognizing the syndrome · Full Atlas view
- Recovery from catatonia follows a hierarchical precision order · Full Atlas view
- Recovery from catatonia follows a hierarchical precision order · Full Atlas view
- Recurrent Catatonia During Longitudinal Evaluation of Possible Seronegative Autoimmune Encephalitis: A Case Report. · Full Atlas view
- Recurrent Catatonia During Longitudinal Evaluation of Possible Seronegative Autoimmune Encephalitis: A Case Report. · Full Atlas view
- Recurrent Catatonia During Longitudinal Evaluation of Possible Seronegative Autoimmune Encephalitis: A Case Report. · Full Atlas view
- Recurrent Catatonia and Demyelinating Disorders. · Full Atlas view
- Recurrent Catatonia and Demyelinating Disorders. · Full Atlas view
- Recurrent Catatonia and Demyelinating Disorders. · Full Atlas view
- Recurrent Catatonia due to Episodic Obsessive-Compulsive Disorder. · Full Atlas view
- Recurrent Catatonia due to Episodic Obsessive-Compulsive Disorder. · Full Atlas view
- Recurrent Catatonia due to Episodic Obsessive-Compulsive Disorder. · Full Atlas view